Europe — EMA

Odelniqva (Dapagliflozin)

Dapagliflozin, the active ingredient in Odelniqva, is a SGLT2 inhibitor presented as a tablet for oral use. It helps manage blood glucose levels in adults with type 2 diabetes mellitus.

Dapagliflozin

Request sourcing

Pack/s

What is Dapagliflozin?

Dapagliflozin, the active ingredient in Odelniqva, is a SGLT2 inhibitor presented as a tablet for oral use. It helps manage blood glucose levels in adults with type 2 diabetes mellitus. GNH USA supplies Odelniqva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

GNH USA supplies Odelniqva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

What is Dapagliflozin used for?

Odelniqva is a SGLT2 inhibitor that improves - Type 2 diabetes mellitus: It ... - ... .... ... … ... ... … … … … … … … … … - .... … ...

What are the side effects of Dapagliflozin?

Common

Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.

Send a sourcing enquiry for this product →